Great find, Huts! Seems like the same template for the IP deal we have. Going after the Chinese market could get this quicker to commercialization and royalties for CDMO shareholders. I like the business model.
"1) DNA-based TLR9 agonists (dSLIM® (Lefitolimod) and EnanDIM®)- With its dSLIM® DNA molecule, MOLOGEN has created a modern tool capable of exerting a specific influence on the patient's immune system (a process known as immunomodulation). Of note is the fact that this immunomodulator is extremely versatile and can be used for a variety of possible applications in the field of cancer treatments and potentially also in the field of infectious diseases. It can also be used as an enhancer (or adjuvant) in combination with other treatment approaches or drugs."
News 
Market Data 
Discover 
AI
